Effective post-laparoscopic treatment of endometriosis with dydrogesterone.
An open, prospective, multicenter study was designed to assess the efficacy and safety of dydrogesterone in the post-laparoscopic treatment of endometriosis in Indian patients. Ninety-eight patients suffering from minimal, mild, moderate or severe endometriosis, with or without infertility, who had undergone laparoscopy, were treated with dydrogesterone 10 mg/day (or 20 mg/day in severe cases) orally from day 5 to day 25 of each cycle for 3-6 months. Pelvic pain, dysmenorrhea and dyspareunia improved significantly (p < 0.05) after the first cycle of treatment. By the end of the sixth cycle, the reduction in pelvic pain, dysmenorrhea and dyspareunia was 95%, 87% and 85%, respectively. The amount of menstrual bleeding fell significantly (p < 0.05) after 2 months (-12%) and this significant reduction was maintained until the end of the study. The duration of bleeding was also reduced significantly (p < 0.05) throughout the study, starting after the first month of treatment (-10%). A total of 21.1% of the patients were considered cured and 66.7% showed improvement. Overall, dydrogesterone therapy was rated as excellent to good by 74% of patients and 70% of physicians. No adverse events were reported. In conclusion, dydrogesterone is an effective and safe post-laparoscopic treatment for endometriosis.
Trivedi
Prakash
P
National Institute of Laser and Endoscopic Surgery, AAKAR IVF Centre, Mumbai, India. ptrivedi@bom5.vsnl.net.in
Selvaraj
Kamala
K
Mahapatra
P Das
PD
Srivastava
Saroj
S
Malik
Sonia
S
D000328:Adult; D003131:Combined Modality Therapy; D004394:Dydrogesterone / Q000627:therapeutic use*; D004412:Dysmenorrhea / Q000188:drug therapy; D004414:Dyspareunia / Q000188:drug therapy; D004715:Endometriosis / Q000188:drug therapy* / Q000601:surgery*; D005260:Female; D006801:Humans; D010535:Laparoscopy; D008875:Middle Aged; D017060:Patient Satisfaction; D017699:Pelvic Pain / Q000188:drug therapy; D011372:Progestins / Q000627:therapeutic use*; D011446:Prospective Studies
D011372:Progestins; D004394:Dydrogesterone